{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:20Z","timestamp":1794029060242,"version":"4.8.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01344-3","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T14:13:45Z","timestamp":1755785625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4156-3165","authenticated-orcid":false,"given":"Jules","family":"Higu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0824","authenticated-orcid":false,"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Barri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti","family":"Chantzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-8377","authenticated-orcid":false,"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Joelle","family":"Mozziconacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-7974","authenticated-orcid":false,"given":"Lauren","family":"V\u00e9ron\u00e8se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-3154","authenticated-orcid":false,"given":"C\u00e9dric","family":"Pastoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Tondeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6258-7028","authenticated-orcid":false,"given":"Pascale","family":"Flandrin-Gresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lachot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Cazaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Th\u00e9pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8310","authenticated-orcid":false,"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspar","family":"Aspas Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"1344_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"1344_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1344_CR3","doi-asserted-by":"publisher","first-page":"e345570d","DOI":"10.1097\/01.HS9.0000968920.34557.0d","volume":"7","author":"N Potter","year":"2023","unstructured":"Potter N, Jovanovic J, Ivey A, Thomas A, Wilhelm-Benartzi C, Gilkes A, et al. P503: A Randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid Leukaemia: results from the UK NCRI AML17 and AML19 studies. Hemasphere. 2023;7:e345570d.","journal-title":"Hemasphere"},{"key":"1344_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","volume":"38","author":"C Orvain","year":"2024","unstructured":"Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, et al. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study. Leukemia. 2024;38:1949\u201357.","journal-title":"Leukemia"},{"key":"1344_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16857","volume":"191","author":"A Bataller","year":"2020","unstructured":"Bataller A, O\u00f1ate G, Diaz-Bey\u00e1 M, Guijarro F, Garrido A, Vives S, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191:52\u201361.","journal-title":"Br J Haematol"},{"key":"1344_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143:11\u201320.","journal-title":"Blood"},{"key":"1344_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","volume":"8","author":"C Jimenez-Chillon","year":"2024","unstructured":"Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, et al. Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML. Blood Adv. 2024;8:343\u201352.","journal-title":"Blood Adv"},{"key":"1344_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00928-1","volume":"13","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang X, Xu Y, Xue S, Qiu H, Tang X, et al. Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood Cancer J. 2023;13:155.","journal-title":"Blood Cancer J"},{"key":"1344_CR9","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213\u201323.","journal-title":"Blood"},{"key":"1344_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood-2023-179376","volume":"142","author":"HB Mathilde","year":"2023","unstructured":"Mathilde HB, Pautas C, Bertoli S, Dumas PY, Raffoux E, Marchand T, et al. Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups. Blood. 2023;142:967.","journal-title":"Blood"},{"key":"1344_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1344_CR12","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1200\/JCO.23.01599","volume":"42","author":"IS Tiong","year":"2024","unstructured":"Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, et al. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). J Clin Oncol. 2024;42:2161\u201373.","journal-title":"J Clin Oncol"},{"key":"1344_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","volume":"7","author":"GC Issa","year":"2023","unstructured":"Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023;7:933\u201342.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01344-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:00:04Z","timestamp":1757412004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01344-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sarah Bertoli declares a consulting or advisory role with Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals as well as Servier and received travel grants from Abbvie and Pfizer. Christian R\u00e9cher declares a consulting or advisory role with Abbvie, Amgen, Astellas, BMS, Boehringer, Daiichi-Sankyo, Jazz Pharmaceuticals, Janssen and Servier, received research funding from Abbvie, Amgen, Astellas, BMS, Daiichi-Sankyo, Iqvia and Jazz Pharmaceuticals, and support for attending meetings and\/or travel from Abbvie, Novartis and Servier. Arnaud Pigneux declares a consulting or advisory role with Astellas, BMS, Servier, Abbvie, Gilead, Jazz Pharmaceuticals, Novartis, Pfizer, received research funding from Astellas, BMS, Roche, Servier and support for attending meetings and\/or travel from Servier, Abbvie. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}